title: [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.
abstract: BACKGROUND
  [123I]beta-CIT and SPECT imaging of the dopamine transporter is a sensitive biomarker of PD onset and severity.
  
  
  OBJECTIVE
  In this study, the authors examine the change in [123I]beta-CIT uptake in sequential SPECT scans to assess the rate of progression of the dopaminergic terminal loss in patients with PD.
  
  
  METHODS
  Patients with PD (n = 32) and healthy controls (n = 24) recruited from the Yale Movement Disorders Center underwent repeat [123I]beta-CIT SPECT imaging during a 1- to 4-year period. The primary imaging outcome was the ratio of specific to nondisplaceable striatal activity. Disease severity was assessed by Hoehn and Yahr staging, and Unified Parkinson Disease Rating Scale after 12 hours off drug.
  
  
  RESULTS
  Sequential SPECT scans in PD subjects demonstrated a decline in [123I]beta-CIT striatal uptake of approximately 11.2%/year from the baseline scan, compared with 0.8%/year in the healthy controls (p < 0.001). Although [123I]beta-CIT striatal uptake in the PD subjects was correlated with clinical severity, the annual percentage loss of [123I]beta-CIT striatal uptake did not correlate with the annual loss in measures of clinical function.
  
  
  CONCLUSIONS
  - The rate of dopaminergic loss in PD is significantly greater than that of healthy controls, and [123I]beta-CIT SPECT imaging provides a quantitative biomarker for the progressive nigrostriatal dopaminergic degeneration in PD. As new protective and restorative therapies for PD are developed, dopamine transporter imaging offers the potential to provide an objective endpoint for these therapeutic trials.
authors.affiliation: Department of Neurology, Yale University School of Medicine, New Haven, CT, USA. kmarek@indd.org
authors.forename: K
authors.initials: K
authors.lastname: Marek
authors.forename: R
authors.initials: R
authors.lastname: Innis
authors.forename: C
authors.initials: C
authors.lastname: van Dyck
authors.forename: B
authors.initials: B
authors.lastname: Fussell
authors.forename: M
authors.initials: M
authors.lastname: Early
authors.forename: S
authors.initials: S
authors.lastname: Eberly
authors.forename: D
authors.initials: D
authors.lastname: Oakes
authors.forename: J
authors.initials: J
authors.lastname: Seibyl
mesh_terms: D000368:Aged; D002421:Caudate Nucleus / Q000000981:diagnostic imaging / Q000503:physiopathology; D003042:Cocaine / Q000031:analogs & derivatives*; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000503:physiopathology; D018450:Disease Progression; D004292:Dominance, Cerebral / Q000502:physiology; D050483:Dopamine Plasma Membrane Transport Proteins; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins / Q000502:physiology; D008875:Middle Aged; D009419:Nerve Tissue Proteins; D009460:Neurologic Examination; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000503:physiopathology; D011699:Putamen / Q000000981:diagnostic imaging / Q000503:physiopathology; D012016:Reference Values; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; C069723:2beta-carbomethoxy-3beta-(4-iodophenyl)tropane; D003042:Cocaine